This week, our quest to accelerate high-impact technologies to patients took our CEO, David Hochman, to Jefferies Global Healthcare Conference, joining over 500 public and private healthcare companies, institutional and private equity investors, and VCs. "The Jefferies Global Healthcare Conference has become the premier annual healthcare investment event in Europe, bringing innovators together with global market leaders and institutional investors. It’s always exciting to attend and represent Orchestra BioMed in these conversations as we continue to advance our high-impact therapies and partnership-enabled business model." – David Hochman, Chairman, CEO & Founder #JefferiesHealthcare #Cardiology #MedTech
Orchestra BioMed
生物技术研究
A biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine.
关于我们
Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Under these collaborations, Orchestra BioMed advances its promising therapeutic solutions through late-stage clinical research and regulatory approvals, while its collaborators focus on leveraging their commercial expertise and existing infrastructure to bring these product candidates to global markets quickly and efficiently. Orchestra BioMed’s lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT?)) for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing Virtue? Sirolimus AngioInfusion? Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed has additional product candidates and plans to potentially expand its product pipeline through acquisitions, strategic collaborations, licensing and organic development. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com.
- 网站
-
https://www.orchestrabiomed.com
Orchestra BioMed的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 类型
- 上市公司
- 创立
- 2017
Orchestra BioMed员工
动态
-
Our team is driven by four core values: We Care, We Are Creative, We Are Driven and We Deliver. For #NationalCareerDevelopmentMonth, we’re sharing advice from our leaders that reflect these pillars and how they fuel personal and professional growth. #OrchestratingInnovation #CareerDevelopment #TeamofInnovators
-
Living with cardiovascular disease can come with enough challenges, which is why we believe the treatment options should be seamless and impactful. Co-Primary Investigator on our BACKBEAT study and Chief Scientific Officer at Piedmont, Dr. David Kandzari, gives insight into the significant role innovation plays in transforming care for patients with unmet needs. Learn more: https://lnkd.in/e59pKDeK #TeamofInnovators #Innovation #MedTech
-
-
Find our Q3 2024 financial results and business updates here: https://lnkd.in/gBbWrnbh #OrchestratingInnovation #News
-
-
Next week at the Jefferies conference, our CEO, David Hochman, will participate in a fireside chat with Jefferies #Medtech analyst Matt Taylor, CFA. We’d love to see you there! https://lnkd.in/eB3p-_RG #JefferiesHealthcare
-
-
Congratulations to our colleagues on the Vivasure Medical Ltd. team for their announcement of positive IDE study results at #TCT2024! These initial findings from the PATCH IDE pivotal study mark an exciting advancement for large-hole closure in structural interventions. As a strategic shareholder of Vivasure, we are proud to support #innovation in #Cardiology.
Today, we announced initial positive results from the U.S. IDE PATCH Pivotal Study evaluating the safety and efficacy of the Vivasure PerQseal? Closure Device System – a technology designed to change the way cardiologists perform large hole closure for structural interventions. Results demonstrate that PerQseal achieved closure with very low rates of major vascular complications and rapid times to hemostasis. Learn more: https://lnkd.in/dtVdEWKx #TCT2024 #Cardiology #MedDevice
-
-
Orchestra BioMed was excited to send a strong contingent of our team David Hochman, Darren R. Sherman, Amy Orlick Berman, Hans-Peter Stoll, John Sieckhaus, Avi Fischer, Heather Buckley, and Bill Little to Washington for #TCT2024 where we met with leading researchers, clinicians and #MedTech innovators from around the globe. "Collaboration with partners and those who share our passion for innovation is critical to the work we do in advancing new therapies to patients. We're grateful for these opportunities that allow us to continue building impactful partnerships with industry leaders and experts." – Amy Berman, VP, Clinical Operations It was a pleasure to attend! #OrchestratingInnovation
-
-
We’re proud to announce that our EVP of Corporate Development & Strategy, Bill Little, will be joining an esteemed panel at #InnovationSanDiego to explore critical insights on funding and innovation in the #MedTech sector. Bill will share the stage with industry leaders Greg Garfield of KCK Medtech and Chris Neil of MedTech Advantage Fund. We look forward to a dynamic exchange of ideas. #OrchestratingInnovation
Join Orchestra BioMed's Bill Little, KCK Medtech's Greg Garfield, and MedTech Advantage Fund's Chris Neil at Innovation Summit San Diego 2024 in the panel session "Getting Funding From New Sources." ??? Stephen Levin, Editor-in-Chief of Market Pathways, will be moderating the discussion featuring these esteemed panelists on Thursday, November 21 from 8:45-9:25AM: Bill Little joined Orchestra BioMed as its Executive Vice President of Corporate Development and Strategy in June 2023, bringing an extraordinary depth of knowledge, expertise and relationships in the #cardiovascular device industry. Greg Garfield currently serves as Senior?Managing Director,?and the head of KCK's Medtech Group. KCK Medtech is an evergreen #investment fund whose flexible capital and operationally experienced team brings significant?value in building companies. The KCK Medtech Team is composed of operators and leaders from both start up and fortune 500 companies. Chris Neil is an experienced venture & angel investor, senior executive, and start-up advisor. He is Partner and Co-Founder of MedTech Advantage Fund, investing in a broad portfolio of #medtech, biotools, and digital health start-ups that have graduated from the MedTech Innovator accelerator program. Welcome to #InnovationSanDiego, Bill, Greg, and Chris! Climb the Summit to MedTech Innovation November 19-21, 2024 at The US Grant Hotel in San Diego, California to easily connect and network with the industry's top key players without the typical conference hurdles. Register today: https://bit.ly/4gBjKW6
-
Did you know that atherosclerotic artery disease is one of the leading causes of cardiovascular problems? We are working to develop an innovative treatment option to help patients manage this condition effectively. Learn more about our work with partners to bring these solutions to life: https://lnkd.in/gVMS9keg #Partnerships #Innovation #MedTech
-
-
Thank you to all of our employees, friends, and family around the globe who participated in the #WorldHeartDay challenge with us. Collectively, we walked and cycled 166 km! #Cardiology #MedTech World Heart Federation